BGNE

BeiGene Ltd.

This asset is no longer available for investment.

View all assets

Price

return (12m)

0.00%

p/e

-22.41

p/bv

5.61

DIVIDEND YIELD

0.00%

BGNE price

BeiGene

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BGNE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals BGNE

Valuation

P/E

-22.41

Sector -66.00

Industry -66.00

P/BV

5.61

Sector -3.00

Industry -3.00

P/Revenue (PSR)

5.81

Sector -7.80

Industry -7.80

EV/EBITDA

-342.37

Sector -40,748,258.36

Industry -40,748,258.36

EV/EBIT

-139.40

Sector -43,475,809.65

Industry -43,475,809.65

P/EBITDA

-26.51

Sector -1,341.27

Industry -1,341.27

P/EBIT

-22.10

Sector -448.79

Industry -448.79

P/Total Assets

3.31

Sector 1.05

Industry 1.05

P/Net Current Assets

12.71

Sector -12,585,111.43

Industry -12,585,111.43

P/Working Capital

10.22

Sector -3,247,398.66

Industry -3,247,398.66

EPS

-8.12

Sector -12,227.97

Industry -12,227.97

BVPS

32.42

Sector -5,764.06

Industry -5,764.06

Efficiency

Gross Margin

83.74%

Sector 23.92%

Industry 23.92%

EBITDA Margin

-4.89%

Sector -16,313.59%

Industry -16,313.59%

EBIT Margin

-12.01%

Sector -4,256,416.89%

Industry -4,256,416.89%

Operating Margin

-26.31%

Sector -53.16%

Industry -53.16%

Net Profit Margins

-25.94%

Sector -54.70%

Industry -54.70%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

-25.04%

Sector -3,314.88%

Industry -3,314.88%

ROA

-14.76%

Sector -295.98%

Industry -295.98%

ROIC

-19.43%

Sector -2,109.21%

Industry -2,109.21%

Dividends

Dividend yield

0.00%

Sector -1.03%

Industry -1.03%

Payout

Sector -

Industry -

Debt

Current Ratio

1.93

Sector 2.90

Industry 2.90

Net Debt / EBITDA

51.35

Sector -6.09

Industry -6.09

Net Debt / EBIT

20.91

Sector -3.13

Industry -3.13

Net Debt / Equity

-0.73

Sector -1.08

Industry -1.08

Gross Debt / Equity

0.05

Sector 0.00

Industry 0.00

Equity/Assets

0.59

Sector -0.25

Industry -0.25

Liabilities/Assets

0.59

Sector 0.13

Industry 0.13

Growth

5Y Revenue CAGR

23.04%

Sector -

Industry -

5Y Earnings CAGR

-9.45%

Sector -

Industry -

Fundamentals BGNE

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BGNE BeiGene Ltd.	$0.00	-	0.00%	-22.41	5.61	-25.04%	-25.94%
JNJ Johnson & Johnson	$260.56	53.94%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$26.78	15.88%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$249.75	29.02%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.08	-4.01%	4.00%	11.36	6.03	53.11%	35.32%
MRK Merck & Co. Inc.	$134.41	68.99%	2.49%	105.02	7.94	7.56%	4.77%
AZN AstraZeneca PLC	$155.78	1.68%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$63.93	39.94%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$74.44	-50.06%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$802.27	42.53%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$412.19	47.64%	2.38%	25.46	19.04	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$98.35	51.01%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$866.22	31.29%	0.37%	22.83	-80.58	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$507.39	28.15%	0.00%	29.26	6.36	21.76%	35.00%
HRMY Harmony Biosciences Holdings Inc.	$38.08	3.85%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$208.88	54.51%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BGNE Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT BeiGene

BeiGene Ltd.

Average Investor10 user rating

4.0 (5 people)

United States

16 years

Founded: 2010

2016

Time since IPO - 10 years

5.300

Employees

BeiGene Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $19.28 billion, with shareholders equity totaling $3.44 billion.

The company employs approximately 5.300 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, BeiGene Ltd. reported $3.32 billion in revenue, generating net income of $-860.46 million.

Key financial metrics include a P/E ratio of -22.41, a price-to-book (P/B) ratio of 5.61, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BGNE.

Market cap

$19.28 billion

Net worth

$3.44 billion

$3,436,070,000.00

Assets

$5.83 billion

$5,830,860,000.00

Total Shares Outstanding

106.00 million

106,000,000

Average Daily Trading Volume

$362.69 Thousand

$362,686.04

Sector

Health Care

Industry

Biotechnology

BGNE

BGNE revenue and profits

Financial Results BGNE

DRAG THE FRAME TO SEE MORE DATA

BGNE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

JNJ - Johnson & Johnson

$260.56 51,21% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$249.75 24,69% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

AZN - AstraZeneca

$155.78 0,17% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$26.78 13,98% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BMY - Bristol-Myers Squibb

$63.93 38,24% (12M)

P/E

14.06

3.93%

ROE

41.59%

P/BV

5.85

AMGN - Amgen

$412.19 43,19% (12M)

P/E

25.46

2.38%

ROE

74.80%

P/BV

19.04

GILD - Gilead Sciences

$137.71 19,32% (12M)

P/E

-52.83

2.34%

ROE

-27.59%

P/BV

14.58

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

JNJ - Johnson & Johnson

$260.56 51,21% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$249.75 24,69% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

AZN - AstraZeneca

$155.78 0,17% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$26.78 13,98% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

BMY - Bristol-Myers Squibb

$63.93 38,24% (12 M)

P/L

14.06

3.93%

ROE

41.59%

P/VP

5.85

AMGN - Amgen

$412.19 43,19% (12 M)

P/L

25.46

2.38%

ROE

74.80%

P/VP

19.04

GILD - Gilead Sciences

$137.71 19,32% (12 M)

P/L

-52.83

2.34%

ROE

-27.59%

P/VP

14.58

Frequently Asked Questions

What is the price of BeiGene (BGNE) today?

A cotação de BeiGene (BGNE) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de BeiGene (BGNE) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de BeiGene (BGNE) e dados de ações do Ibovespa e mercados internacionais.

Quando BeiGene (BGNE) paga dividendos?

BeiGene (BGNE) não distribuiu dividendos no último ano.

Is BeiGene (BGNE) a good investment?

Atualmente, BeiGene (BGNE) está cotada a US$ 0.00, com um P/L de -22.41, representando um desvio de -6,406% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy BeiGene (BGNE) stock?

Investir em ações de BeiGene (BGNE) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of BeiGene (BGNE) yield today?

A rentabilidade de BeiGene (BGNE) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de BeiGene (BGNE) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BGNE

BeiGene Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BGNE

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING BGNE WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT BeiGene

BeiGene Ltd.

United States

16 years

2016

5.300

PROFIT X PRICE BGNE

Financial Results BGNE

BGNE cash flow

Asset, Revenue and Profit Growth - BGNE

BGNE balance sheet

BFRA - Biofrontera

JNJ - Johnson & Johnson

ABBV - AbbVie

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

AMGN - Amgen

GILD - Gilead Sciences

BFRA - Biofrontera

JNJ - Johnson & Johnson

ABBV - AbbVie

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

AMGN - Amgen

GILD - Gilead Sciences

Frequently Asked Questions